Overview

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Status:
Not yet recruiting

Trial end date:
2025-06-04

Target enrollment:

Participant gender:

Summary

This study will assess the efficacy and safety of the combination of ceralasertib and durvalumab versus standard of care docetaxel in patients with locally advanced and metastatic NSCLC after progression on prior anti-PD-(L)1 therapy and platinum-based chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Docetaxel
Durvalumab